Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

NCT06427811 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Interventions

DRUG: Asciminib

Sponsor

Novartis Pharmaceuticals